{"url_path":"/sec/vbio/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-004481-index.html","accession_number":"0001683168-26-004481","cik":"0001787740","ticker":"VBIO","issuer_name":"Valion Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-004481-index.html","primary_entity_key":"0001787740","primary_entity_name":"Valion Bio, Inc."},"word_count":92,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n** **\n\n \n(d)\nExhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n10.1\n \n[Second Amendment to Valion Bio, Inc. Amended and Restated 2021 Equity Incentive Plan, dated May 28, 2026](valion_ex1001.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 4 \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n  \n\n \n \n \n**VALION BIO, INC.**\n\n \n \n \n \n\n \n \n \n \n\nDate:\nJune 3, 2026\nBy:\n*/s/ Lisa Wolf*\n\n \n \n \nName: Lisa Wolf\n\nTitle: Chief Financial Officer\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 5"}